Alterations of the TP53 gene and TP53 protein expression in epithelial ovarian cancer before and after chemotherapy

International Journal of Clinical Oncology

Volumn 3, Issue 4, 1998, Pages 240-246

  Okada, Makoto ^a   Kigawa, Junzo ^a   Minagawa, Yukihisa ^a   Kanamori, Yasunobu ^a   Itamochi, Hiroaki ^a   Cheng, Xiusi ^a   Ohishi, Tetsuro ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Chemoresistance; Mutation; Ovarian cancer; p53; TP53; TP53 protein

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SECOND LOOK SURGERY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0031689106     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02489840     Document Type: Article

References (34)

1. Muggia FM. Cisplatin update. Semin Oncol 1991;18:1-4.
2. Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Terakawa N. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer 1993;72:804-808.
3. Andrews PA, Velury S, Mann SC, Howell SB. Cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988;48:68-73.
4. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990;2:35-43.
5. Fujiwara Y, Sugimoto Y, Kasahara K, Bungo M, Yamakido M, Tew KD, Saijo N. Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn J Cancer Res 1990;81:527-535.
6. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsda T, Saijo N. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 1991;51:3237-3242.
7. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988;48: 5713-5716.
8. Kellen JA. Molecular interrelationships in multidrug resistance. Anticancer Res 1994;14:433-435.
9. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993;74:777-779.
10. Kastan MB, Canman CE, Leonard CJ. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995;14:3-15.
11. H. Lu SJ, Man S, Bani MR, Adachi D, Hawley RG, Kerbel RS, Ben David-Y. Retroviral insertional mutagenesis as a strategy for the identification of genes associated with cis-diamminedichloroplatinum (II) resistance. Cancer Res 1995;55:1139-1145.
12. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-318.
13. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-562.
14. Landesman Y, Bringold F, Kimchi A. p53 undergoes epitopic changes in vitro by sodium-vanadate. Oncogene 1994;9:1241-1245.
15. Russmann H, Schmidt H, Caprioli A, Krach H. Highly conserved B-subunit genes of Shiga-like toxin II variants found in Escherichia coli O157 strains. FEMS Microbiol Lett 1994;118:335-340.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
17. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995;11:1217-1228.
18. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
19. Wang XW, Yeh H, Schaeffer L, Roy R, Monocollin V, Egly JM, Wang Z, Friedberg EC, Evans MK, Taffe BG, Bohr VA, Weeda G, Hoeijmakers JHJ, Forrester K, Harris CC. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet 1995;10:188-195.
20. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino FA. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-693.
21. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995;87: 1254-1256.
22. Herod J, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian cancer. Cancer Res 1996;56:2178-2184.
23. Lundin J, Nordling S, von Boguslawsky K, Roberts PJ, Haglund C. Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology 1996;53:104-111.
24. Aas T, Borresen AL, Geisler, S, Smith SB, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-814.
25. Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, Terakawa N. Glutathione S-transferase-π expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer 1997;79:521-527.
26. Greenblatt MS, Bennette WP, Hollstein M, Harris CC. Mutation in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
27. Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL. Prognostic significance of p53 gene alterations in node- negative breast cancer. Breast Cancer Res Treat 1993;26:225-235.
28. Diccianni MB,Yu J, Hsiao M, Mukherjee S, Shao LE, Yu AL. Clinical significance of p53 mutation in relapsed T-cell acute lymphoblastic leukemia. Blood 1994;84:3105-3107.
29. Kraiss S, Spiess S, Reihsaus E, Montenarh M. Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 with cell transformation. Exp Cell Res 1991;192:157-164.
30. Maestro R, Dolcetti R, Gasparotto D, Doglioni C, Pelucchi S, Barzan L, Grandi E, Boiocchi M. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992;7:1159-1166.
31. Fritsche M, Haessler C, Brandner G. Nuclear accumulation of p53: an indicator of chromatin injury? J Cancer Res Clin Oncol 1991;117:30 (abstr).
32. Tsuda H, Hirohashi S. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer 1994;57:498-503.
33. Lam KY, Tsao SW, Zhang D, Law S, He D, Ma L, Wong J. Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: a prospective clinicopathological study and survival analysis of 70 patients. Int J Cancer 1997;74:212-219.
34. Calzolari A, Chiarelli I, Bianchi S, Messerini L, Gallo O, Porfirio B, Mattiuz PL. Immunohistochemical vs molecular biology methods. Complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol 1997;107:7-11.